Stock Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Stock Screener
Compare Stocks
Penny Stock Screener
Top Product Insights Stocks
Daily Updates
Daily Analyst Ratings
Trending Stocks
Top Stock Gainers
Top Stock Losers
Most Active Stocks
Dividend Stocks
ChatGPT Stocks
New
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Market Holidays
Stock Ideas
ETF Research Tools
ETF Center
ETF Screener
Top ETFs by Smart Score
New
Compare ETFs
Top ETFs by AUM
ETFs On the Move
Top ETF Gainers
Top ETF Losers
Most Active ETFs
ETF Ideas
S&P 500 Index ETFs
Nasdaq 100 Index ETFs
S&P 500 Sector ETFs
Bond ETFs
Commodity ETFs
Currency ETFs
Industry ETFs
ETFs
Best Dividend Stocks
Best High Yield Dividend Stocks
Dividend Aristocrats
New
Dividend Stock Comparison
Dividend Calculator
Popular
Dividend Returns Comparison
Dividend Calendar
Dividends
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
My Portfolio
My Watchlist
My Performance
My Portfolio Analysis
Crowd Insights
Portfolio
Stock Market News
Stock Analysis & Ideas
Popular
ETF News
Global Markets News
Expert Spotlight
TipRanks Labs
Earnings Reports Insights
Market Breakdowns
Dividend Stock News
Crypto News
News
Education
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
TipRanks Community
Careers
Contact Us
Working with TipRanks
Enterprise Solutions
Best Online Brokers
Become an Affiliate
Follow Us
More...
Plans
News
Smart Portfolio
Expert Center
Ideas
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
ETF Center
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed Tools
Try Now
Stock Ideas
Stock Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Stock Screener
Compare Stocks
Penny Stock Screener
Top Product Insights Stocks
Options Profit Calculator
New
Daily Updates
Daily Analyst Ratings
Trending Stocks
Top Stock Gainers
Top Stock Losers
Most Active Stocks
Dividend Stocks
ChatGPT Stocks
New
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Market Holidays
ETFs
ETF Research Tools
ETF Center
ETF Screener
New
Top ETFs by Smart Score
New
Compare ETFs
Top ETFs by AUM
ETFs On the Move
Top ETF Gainers
Top ETF Losers
Most Active ETFs
ETF Ideas
S&P 500 Index ETFs
Nasdaq 100 Index ETFs
S&P 500 Sector ETFs
Bond ETFs
Commodity ETFs
Currency ETFs
Industry ETFs
Dividends
Best Dividend Stocks
Best High Yield Dividend Stocks
Dividend Aristocrats
New
Dividend Stock Comparison
Dividend Calculator
Popular
Dividend Returns Comparison
Dividend Calendar
Crypto
Crypto Center
Bitcoin
Ethereum
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Portfolio
My Portfolio
My Watchlist
My Performance
My Portfolio Analysis
Crowd Insights
News
Stock Market News
Stock Analysis & Ideas
Popular
ETF News
Global Markets News
Expert Spotlight
TipRanks Labs
Earnings Reports Insights
Market Breakdowns
Dividend Stock News
Crypto News
More
Education
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
TipRanks Community
Careers
Contact Us
Working with TipRanks
Enterprise Solutions
Best Online Brokers
Become an Affiliate
Follow Us
Plans & Pricing
PCVX
Stock Latest News
Press Releases
Vaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update
24d ago
PCVX
Press Releases
Vaxcyte Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
1M ago
PCVX
The Fly
Vaxcyte 11.2M share Secondary priced at $41.00
1M ago
PCVX
Press Releases
Vaxcyte Announces Pricing of $500 Million Public Offering
1M ago
PCVX
The Fly
Vaxcyte initiated with an Outperform at TD Cowen
1M ago
PCVX
The Fly
Vaxcyte price target raised to $68 from $63 at BofA
1M ago
PCVX
Press Releases
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
1M ago
PCVX
The Fly
Vaxcyte announces offering of common stock, warrants
1M ago
PCVX
Market News
New Vaccine Data Sends Vaxcyte Stock Blasting Up
1M ago
PFE
PCVX
Press Releases
Vaxcyte Reports Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, in Adults Aged 65 and Older and Full Six-Month Safety Data from Adult Phase 1/2 and Phase 2 Studies
2M ago
PCVX
The Fly
Vaxcyte reports ‘positive’ results from Phase 2 study of VAX-24
2M ago
PCVX
Press Releases
Vaxcyte to Host Webcast and Conference Call to Discuss Results from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate in Adults Aged 65 and Older and Full Six-Month Safety Data from Both Adult Phase 2 Studies
2M ago
PCVX
The Fly
Vaxcyte doses first participants in Phase 2 study of VAX-24
2M ago
PCVX
Press Releases
Vaxcyte Doses First Participants in Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
2M ago
PCVX
Press Releases
Vaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
3M ago
PCVX
The Fly
Vaxcyte announces FDA clearance of IND for VAX-24
3M ago
PCVX
Press Releases
Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
3M ago
PCVX
Press Releases
Vaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023
3M ago
PCVX
Press Releases
Vaxcyte to Present at the SVB Securities Global Biopharma Conference
4M ago
PCVX
The Fly
Vaxcyte’s VAX-24 granted FDA Breakthrough Therapy designation
5M ago
PCVX
Press Releases
Vaxcyte’s VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults
5M ago
PCVX
The Fly
Vaxcyte named as Top Pick, added to Conviction list at Needham
5M ago
PFE
APLS
Show More
You need to enable JavaScript to run this app.